HAR1A, in part, controlled proliferation, migration, invasion, and EMT of NSCLC cells by boosting the interaction between ANXA2 and its E3 ligase TRIM65 and thereby disintegrating oncogenic ANXA2 to inactivate the NF-κB signaling pathway. Here, HAR1A is linked to non-small cell lung carcinoma.